Does increased CCL2-mediated immune cell recruitment during mucosal BCG vaccination provide superior protection against TB?

Affiliations

¹ Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
² Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
³ Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: matthew.long@osumc.edu.

Gregory Serpa et al. Mol Ther. 2024.

. 2024 Nov 6;32(11):3763-3764.

doi: 10.1016/j.ymthe.2024.10.009. Epub 2024 Oct 28.

¹ Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
² Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
³ Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: matthew.long@osumc.edu.

No abstract available

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

1. World Health Organization; Geneva: 2023. Global Tuberculosis Report 2023. License: CC BY-NC-SA 3.0 IGO.
1. Martinez L., Cords O., Liu Q., Acuna-Villaorduna C., Bonnet M., Fox G.J., Carvalho A.C.C., Chan P.C., Croda J., Hill P.C., et al. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. Lancet Glob. Health. 2022;10:e1307–e1316. - PMC - PubMed
1. Guo S., Ouyang J., Hu Z., Cao T., Huang C., Mou J., Gu X., Liu J. Intranasal vaccination with engineered BCG expressing CCL2 induces a stronger immune barrier against Mycobacterium tuberculosis than BCG. Mol Ther. 2024;32:3990–4005. doi: 10.1016/j.ymthe.2024.09.021. - DOI - PubMed
1. Singh V.K., Srivastava R., Srivastava B.S. Manipulation of BCG vaccine: a double-edged sword. Eur. J. Clin. Microbiol. Infect. Dis. 2016;35:535–543. - PubMed
1. Nasser Eddine A., Kaufmann S.H.E. Improved protection by recombinant BCG. Microbes Infect. 2005;7:939–946. - PubMed